ES
ZBIO

Enavate Sciences’s Zenas BioPharma ZBIO Stock Holding History

Enavate Sciences’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$76.6M Hold
3,919,159
– – 21.8% 3
2025
Q4 		$142M Buy
3,919,159
+157,800
+4% +$5.19M 28.08% 1
2025
Q3 		$83.5M Hold
3,761,359
– – 25.5% 1
2025
Q2 		$36.4M Hold
3,761,359
– – 20.65% 3
2025
Q1 		$29.7M Hold
3,761,359
– – 22.39% 2
2024
Q4 		$30.8M Buy
+3,761,359
New +$58.7M 22.12% 3

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Enavate Sciences's ZBIO Position: Q1 2026 in Review

Enavate Sciences held its Zenas BioPharma (ZBIO) position steady in Q1 2026 at 3,919,159 shares worth $76.6M. The position accounts for 21.8% of the portfolio, ranked #3.

Enavate Sciences first reported a position in ZBIO in Q4 2024 and has held it in 6 quarters since. The position peaked at $142M in Q4 2025. 139 funds tracked by Wall St. Rank hold ZBIO as of Q1 2026.

  • Enavate Sciences held 3,919,159 shares of Zenas BioPharma worth $76.6M as of Q1 2026.
  • Enavate Sciences left its Zenas BioPharma share count unchanged in Q1 2026.
  • Zenas BioPharma made up 21.8% of Enavate Sciences's portfolio in Q1 2026, its #3 holding.
  • Enavate Sciences first reported a position in Zenas BioPharma in Q4 2024 and has held it in 6 quarters since.
  • Enavate Sciences's Zenas BioPharma position peaked at $142M in Q4 2025.
  • 139 funds tracked by Wall St. Rank held Zenas BioPharma as of Q1 2026.

Based on Enavate Sciences's 13F filing for Q1 2026, filed 15 May 2026.